Portfolio of Immune Checkpoint Inhibitor Stocks

Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:

• AstraZeneca (AZN) - durvalumab Imfinzi
• Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
• Merck (MRK) - pembrolizumab Keytruda
• Roche Holding (RHHBY) - atezolizumab TECENTRIQ

To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart of portfolio below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 3 stocks included in the portfolio computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the current date in 2009. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.

The current value of a $10,000 investment is $39,027. The percent return is 290.27%. The annualized return is 14.59%.


NOTE: The stocks included in the table and chart are representative of the industry. They are not recommendations.

Related Portfolios

Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Portfolio of Cancer Immunotherapy Stocks

Portfolio of Biotech Stocks

Portfolio of Biotech Stocks: Diabetes